Cravath Guides Ashland In $660M Pharmachem Deal
Ashland, led by Cravath, rolled out a $660 million cash deal for privately owned Pharmachem Laboratories on Monday, allowing the specialty chemicals company to bolster its portfolio with a developer and...To view the full article, register now.
Already a subscriber? Click here to view full article